A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis

Journal of Ophthalmic Inflammation and Infection

Volumn 1, Issue 1, 2011, Pages 29-34

  Phillips, Brandon N ^a   Wroblewski, Keith J ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Corticosteroid sparing agent; Immunomodulatory; Inflammation; Rapamycin; Sirolimus; Uveitis

Indexed keywords

FLUORESCEIN; KETOROLAC; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TRIAMCINOLONE;

ACUTE DISEASE; ADULT; AGED; CASE STUDY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LOWER EXTREMITY DEEP VEIN THROMBOSIS; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; REVIEW; TREATMENT FAILURE; UVEITIS; VISUAL ACUITY;

EID: 84860862862     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1007/s12348-010-0015-5     Document Type: Review

References (17)

1. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study. Ophthalmology 111(3): 491-500.
2. Buhaescu I, Izzedine H, Covic A (2006) Sirolimus-challenging current perspectives. Ther Drug Monit 28: 577-584.
3. Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35(Suppl 3A): 7S-14S.
4. Dutcher JP (2004) Mammalian target of rapamycin inhibition. Clin Cancer Res 10: 63282S-66387S.
5. Hudes GR, Berkenbilt A, Feingold J, Atkins MB, Rini BI, Dutcher J (2009) Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 36(Suppl 3): S26-S36.
6. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A (2010) Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 5: CD004587.
7. Mousa SA, Mousa SS (2010) Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 24(3): 183-194.
8. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140: 509-516.
9. Barakat MR, Kaiser PK (2009) VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18(5): 637-646.
10. Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014.
11. Kleinman DM, Kim DD, Nivaggioli T et al (2007) Sirolimus Inhibits VEGF-Induced Microvascular Hyperpermeability. Invest Ophthalmol Vis Sci 48: 1422.
12. Stahl A, Paschek L, Martin G et al (2008) Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 582(20): 3097-3102, Epub 2008 Aug 12.
13. Martin DF, DeBarge LR, Nussenblatt RD et al (1995) Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 154: 922-927.
14. Shanmuganathan VA, Casely EM, Powell RJ et al (2005) The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 89: 666-669.
15. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD (2007) BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84(1): 83-88.
16. Douglas LC, Yi NY, Davis JL, Salmon JH, Gilger BC (2008) Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther 31(6): 511-516.
17. Manzano RP, Peyman GA, Khan P, Kivilcim M, Chevez-Barrios P, Takahashi W (2009) Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol 72(1): 18-22.